Form 4: SCYNEXIS Director Guy Macdonald Increases Stake with New Stock and Option Grants

SCYNEXIS Inc. Director Guy Macdonald has acquired 23,000 shares of common stock and 23,000 stock options as part of a compensation grant, increasing his beneficial ownership.

Summary

• Guy Macdonald, a Director of SCYNEXIS INC (SCYX), acquired 23,000 shares of common stock on June 26, 2025, at a price of $0.
• Following this transaction, Macdonald beneficially owns 78,000 shares of common stock.
• Macdonald also acquired 23,000 stock options on June 26, 2025, with an exercise price of $0.74.
• The acquired common stock (restricted stock units) and stock options are subject to a vesting schedule where 100% of the shares/options vest on the first anniversary of the grant date, provided the non-employee director continues to provide services.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director's acquisition of shares and options, even as compensation, generally signals confidence in the company's future and aligns insider interests with shareholders. There are no negative elements reported.

Positives

• A director's acquisition of additional shares and options can signal confidence in the company's future prospects and alignment of interests with shareholders.
• The grants are part of a compensation package, indicating ongoing commitment and incentivization for the director's continued service.

Future Outlook

The vesting schedule indicates that the acquired common stock and stock options will fully vest on the first anniversary of the grant date, contingent on the director's continuous service, aligning future incentives with company performance.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing details an insider transaction, specifically a compensation grant to a director. Such grants are common practice across industries to align the interests of company leadership with shareholders and incentivize long-term performance. This specific transaction does not provide broader industry trends but reflects standard corporate governance and compensation practices within the biotechnology or pharmaceutical sector where SCYNEXIS operates.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it indicates a director's increased stake and alignment with shareholder interests, potentially signaling confidence in the company's future.
• Management/Employees: The compensation structure for directors can set a precedent or reflect the company's approach to incentivizing leadership.

Next Steps

• The common stock and stock options are expected to vest on the first anniversary of the grant date (June 26, 2026), provided the director continues to provide services to SCYNEXIS.

Key Dates

Keywords

SCYNEXIS, SCYX, Form 4, Insider Transaction, Director Compensation, Stock Options, Restricted Stock Units, Equity Grant, Beneficial Ownership